

## Azara/Population Health Tool Survey

For the following questions, please respond based on your use of Azara or a third-party population health tool that you use to look at your Electronic Health Record data.

1. Do healthcare providers in your health center use data from Azara or another population health tool dashboards to inform clinical decision making for individual patients?
  - i. Yes, always
  - ii. Yes, some of the time
  - iii. No, never
  - iv. Not sure
  
2. Does your health center use data from Azara or another population health tool dashboards to inform clinical quality improvement efforts related to hypertension control?
  - i. Yes
  - ii. No
  - iii. Not sure

If Yes – How are Azara dashboards used to inform your health center’s clinical quality improvement efforts related to hypertension control?

- [Open Ended]

3. Which of the following measures, does your health center use?

Of the following list of hypertension-related measures available in the Azara platform, please select those your CHC uses for quality improvement, patient tracking, or clinical decision making?

[select all that apply]

- a. Total \_\_\_\_\_ Patients 18 to <85 Years of Age with HTN, #
- b. Total \_\_\_\_\_ Patients in Control (<140/90), #
- c. Total \_\_\_\_\_ Patients in Control (<130/80), #
- d. Improvement in systolic blood pressure in \_\_\_\_\_ Patients, %
- e. Average Encounters per Patient (\_\_\_\_\_), #
- f. Confirmatory Repeated Blood Pressure Measurement in \_\_\_\_\_ Patients, % of visits
- g. Medication Intensification in \_\_\_\_\_ Patients with uncontrolled hypertension, % of visits
- h. Average systolic blood pressure Change After Medication Intensification in \_\_\_\_\_ Patients, mm Hg
- i. Average Visit Interval in \_\_\_\_\_ Patients, days
- j. High BP and Follow-Up Documented in \_\_\_\_\_ Patients

- k. Repeat visit in 4 weeks after uncontrolled HTN in \_\_\_\_\_ Patients, % of visits
- l. Prescription of Fixed Dose Combination Product among patients prescribed at least 2 classes of medications in \_\_\_\_\_ Patients, % of patients
- m. Prescription of a CCB or Thiazide or Thiazide-Like Diuretic among Patients Prescribed At Least One Medication, % of patients
- n. Encounter percentage in \_\_\_\_\_ Patients, where the terminal digit in Systolic/Diastolic BP is zero
- o. Uncontrolled HTN on No Anti-HTN Medications in \_\_\_\_\_ Patients, #
- p. Uncontrolled HTN on Monotherapy in \_\_\_\_\_ Patients, #

4. Which of the following measures does your health center find most useful?

Of the following list of hypertension-related measures available in the Azara platform, please select on a scale of 1 (least useful) to 5 (most useful) how useful the measures are for quality improvement, patient tracking, or clinical decision making?

[select all that apply]

- a. Total \_\_\_\_\_ Patients 18 to <85 Years of Age with HTN, #
- b. Total \_\_\_\_\_ Patients in Control (<140/90), #
- c. Total \_\_\_\_\_ Patients in Control (<130/80), #
- d. Improvement in systolic blood pressure in \_\_\_\_\_ Patients, %
- e. Average Encounters per Patient (\_\_\_\_\_), #
- f. Confirmatory Repeated Blood Pressure Measurement in \_\_\_\_\_ Patients, % of visits
- g. Medication Intensification in \_\_\_\_\_ Patients with uncontrolled hypertension, % of visits
- h. Average systolic blood pressure Change After Medication Intensification in \_\_\_\_\_ Patients, mm Hg
- i. Average Visit Interval in \_\_\_\_\_ Patients, days
- j. High BP and Follow-Up Documented in \_\_\_\_\_ Patients
- k. Repeat visit in 4 weeks after uncontrolled HTN in \_\_\_\_\_ Patients, % of visits
- l. Prescription of Fixed Dose Combination Product among patients prescribed at least 2 classes of medications in \_\_\_\_\_ Patients, % of patients
- m. Prescription of a CCB or Thiazide or Thiazide-Like Diuretic among Patients Prescribed At Least One Medication, % of patients
- n. Encounter percentage in \_\_\_\_\_ Patients, where the terminal digit in Systolic/Diastolic BP is zero
- o. Uncontrolled HTN on No Anti-HTN Medications in \_\_\_\_\_ Patients, #
- p. Uncontrolled HTN on Monotherapy in \_\_\_\_\_ Patients, #